Correlation Between Apolipoprotein E and Recurrent Acute Coronary Syndrome

Document Type : Original Article


1 Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

2 Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

3 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

4 Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

5 Department of Public Health and Preventive Medicine Faculty of Medicine, Airlangga University, Surabaya, Indonesia.

6 Department of Medical Biology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.


Background: Heart disease manifestation due to plaque disruption in the coronary arteries is acute coronary syndrome (ACS). Apolipoprotein-E (Apo-E) is a multifunctional protein with central roles in lipid transportation and metabolism. We analyzed the correlation between the Apo-E blood concentration and recurrent ACS.
Methods: This cross-sectional study recruited 90 patients who visited the outpatient cardiology clinic at Airlangga University Hospital. The patients were divided into 3 groups: without ACS, single ACS, and recurrent ACS. The Apo-E blood concentration was measured using the enzyme-linked immunosorbent assay in the Tropical Disease Center of the Airlangga University Laboratory.
Results: The median Apo-E concentration was 3.6 (1.32-14.9) µg/mL in the recurrent ACS group, 4.01 (2.61-18.54) µg/mL in the single ACS group, and 3.95 (1.19-43.51) µg/mL in the group without ACS. The Kruskal-Wallis test showed no differences in Apo-E between the groups. The χ2 test demonstrated no correlation concerning Apo-E between the single ACS and recurrent ACS groups. The Fisher exact analysis showed no correlation between the Apo-E concentration and dyslipidemia.
Conclusions: Our results showed no correlation between the Apo-E concentration and recurrent ACS. (Iranian Heart Journal 2023; 24(4): 63-69)


  1. World Health Organization (WHO). Cardiovascular diseases (CVDs). Available from: Accessed December 2nd
  2. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL,et al. Group ESCSD 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020: 1-79.
  3. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European Heart Journal. 2015; 36:1163-70.
  4. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med. 2002; 162:2405-10.
  5. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New Engl J Med. 1990; 322(1700).
  6. Frieden C, Wang H, Ho CMW. A mechanism for lipid binding to Apo-E and the role of intrinsically disordered regions coupled to domain-domain interactions. Proc Natl Acad Sci U S A. 2017; 114(24): 6292-97.
  7. Davignon J. Apolipoprotein E and atherosclerosis beyond lipid effect. Arterioscler Throm Vasc Biol. 2005; 25:267- 69.
  8. Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjønneland A, et al. Apolipoprotein C-III and high-density lipoprotein subspecies defined by apolipoprotein C-III in relation to diabetes risk. Am J Epidemiol. 2017; 186(6):736-44.
  9. Jensen MK, Aroner SA, Mukamal KJ, Furtado JD, Post WS, Tsai MY, et al. HDL subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts. Circulation. 2018; 137(13):1364-73.
  10. Zorbozan N, Atikeler GF. Evaluation of high-sensitivity cardiac troponin measurement procedure performance in serum: the vidas 3 high sensitivity cardiac troponin I. International Journal of Biochemistry 2020; 3(3):161-65.
  11. Sofat R, Cooper JA , Kumari M , Casas JP , Mitchell JP , Acharya J, et al. Circulating apolipoprotein E concentration and cardiovascular disease risk: Metaanalysis of results from three studies. Plos Medicine. 2016; 1002146
  12. Basu A, Bebu I, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, et al. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. Journal of Lipid Research.2019; 60.
  13. Mooijaart SP, Jimmy FP, van Heemst D, Havekes LM,  de Craen AJM , Slagboom PE , et al. Apo-E plasma levels and risk of cardiovascular mortality in old age. Plos Medicine. 2006; 3(6):0874-83.
  14. Mendivil CO, Rimm EB, Furtado J, Sacks FM. Apolipoprotein E in VLDL and LDL With Apolipoprotein C-III is Associated With a Lower Risk of Coronary Heart Disease. Journal of the American Heart Association. 2013; 2(000130)
  15. Corsetti JP, Gansevoort RT, Bakker SJL, Navis G, Sparks CE, Dullaart RPF. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein. Metabolism Clinical and Experimental. 2012; 61:996-1002.
  16. Zhong L, Xie YZ, Chao TT, Wang Z, Li X, Shen RC, et al. A Rapid and cost effective method for genotyping apolipoprotein E gene polymorphism. Molecular Neurodegeneration. 2016; 11(2).
  17. Li MY, Kwok MK, Schooling CM. Investigating effects of plasma apolipoprotein E on ischemic heart disease using mendelian randomization study. 2021; 13(2215)
  18. Aditya M, Wahyuni CU, Isfandiari MA. Risk factor analysis of recurrent acute coronary syndrome. Jurnal Berkala Epidemiologi. 2018; 6(3):192-99.
  19. Govender RD, Al-Shamsi S, Soteriades ES, Regmi D. Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study. BMC Cardiovascular Disorders.2019; 19(253).